Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.32 |
| ▸ | AR | P10275 | 3/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.31 |
| ▸ | VEGFA | P15692 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16427704 | 0.82 | ALDH1A1 (0.44) | ARPGR | |
| SCHEMBL15525340 | 0.82 | RIPK1 (0.31) | — | |
| SCHEMBL15367187 | 0.81 | AR (0.46) | AR | |
| SCHEMBL15366964 | 0.81 | KDM4E (0.33) | AR | |
| SCHEMBL15367019 | 0.78 | PDK1 (0.31) | AR | |
| SCHEMBL16733410 | 0.78 | — | — | |
| SCHEMBL15367295 | 0.77 | PDK1 (0.30) | — | |
| SCHEMBL17112790 | 0.77 | HSD17B1 (0.34) | — | |
| SCHEMBL1310561 | 0.76 | ENPP2 (0.48) | AR | |
| SCHEMBL6698447 | 0.76 | ERN1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595964-B1 | Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, processes for their preparation, and pharmaceutical compositions containing them | DOMAINEX LTD (GB) | 2015-04-29 | — | — | EP | disclosed |
| US-8962609-B2 | Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, processes for their preparation, and pharmaceutical compositions containing them | DOMAINEX LIMITED (GB) | 2015-02-24 | — | — | US | disclosed |
| US-20130267491-A1 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMAINEX LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| EP-2595964-A1 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Domainex Limited (GB) | 2013-05-29 | — | — | EP | disclosed |
| WO-2013024282-A2 | COMPOUNDS AND THEIR USES | DOMAINEX LIMITED (GB) | 2013-02-21 | — | — | WO | disclosed |
| WO-2012010826-A1 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMAINEX LIMITED (GB) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267491-A1 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CHUK, IKBKE, TBKBP1 | PLA2G7 2944/4885EPAS1 1787/4885AR 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.